As a result of its ability to predict response to Trastuzumab, which specifically targets human epidermal growth factor receptor 2 (HER2), the assessment of HER2 expression has been incorporated in the diagnostic work-up of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.